// App-Quantinova.ai

LBA11511 : Targeted Therapy for Advanced Solid Tumors Based on Molecular Profiles: Early Results from MyPathway, an Open-Label, Phase IIa Multiple Basket Study

Researchers

Presenter

  • John D. Hainsworth

Principal Investigators

  • Funda Meric-Bernstam

  • Charles Swanton

  • Herbert Hurwitz

  • David R. Spigel

  • Christopher Sweeney

  • Howard A. Burris

  • Ron Bose

  • Shuangli Guo

  • Coen Bernaards

  • Mary Stanley Beattie

  • Alisha Stein

  • Melissa Brammer

  • Razelle Kurzrock

Medical Centers

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • CRUK London Research Institute, London, United Kingdom

  • Duke University Medical Center, Durham, NC

  • Sarah Cannon Research Institute, Nashville, TN

  • Dana-Farber Cancer Institute, Harvard Cancer Center, Boston, MA

  • Washington University School of Medicine, St. Louis, MO

  • Genentech, Inc., South San Francisico, CA

  • Moores Cancer Center, UC San Diego, San Diego, CA

Locations

  • United States

  • United Kingdom

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Epidermal growth factor receptor

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

  • Vemurafenib

  • Pertuzumab

  • Vismodegib

  • Erlotinib hydrochloride

Outcome

  • N/A

Study Design

  • Open Label

  • Cohort

Phase

  • II

Study Id's

  • NCT02091141

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved